Skip to content
10-K

Annual Report

Prevail Therapeutics Inc.

0001564590-20-012986

← back to feed
Filed
Mar 26, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2019 · Mar 26, 2020 34.17M sh
Capex FY 2019 · Dec 31, 2019 $2.14M
Capex FY 2019 · Dec 31, 2018 $627K
Operating Cash Flow FY 2019 · Dec 31, 2019 −$55.75M
Operating Cash Flow FY 2019 · Dec 31, 2018 −$14.01M
Cash And Equivalents FY 2019 · Dec 31, 2019 $168.05M
Cash And Equivalents FY 2019 · Dec 31, 2018 $63.01M
Stockholders Equity FY 2019 · Dec 31, 2019 $165.34M
Stockholders Equity FY 2019 · Dec 31, 2018 −$18.42M
Stockholders Equity FY 2019 · Dec 31, 2017 −$940K
Current Liabilities FY 2019 · Dec 31, 2019 $11.83M
Current Liabilities FY 2019 · Dec 31, 2018 $3.64M
Total Liabilities FY 2019 · Dec 31, 2019 $21.76M
Total Liabilities FY 2019 · Dec 31, 2018 $11.59M
Current Assets FY 2019 · Dec 31, 2019 $174.46M
Current Assets FY 2019 · Dec 31, 2018 $63.58M
Total Assets FY 2019 · Dec 31, 2019 $187.1M
Total Assets FY 2019 · Dec 31, 2018 $72.88M
Sga Expense FY 2019 · Dec 31, 2019 $17.01M
Sga Expense FY 2019 · Dec 31, 2018 $4.68M
Rd Expense FY 2019 · Dec 31, 2019 $48.8M
Rd Expense FY 2019 · Dec 31, 2018 $14.13M
Net Income FY 2019 · Dec 31, 2019 −$63.19M
Net Income FY 2019 · Dec 31, 2018 −$19.09M
Operating Income FY 2019 · Dec 31, 2019 −$65.8M
Operating Income FY 2019 · Dec 31, 2018 −$18.81M
Stock Issued FY 2019 · Jun 30, 2019 7.35M sh